Neuro-Oncology News

The combination of intratumoral DNX-2401 and pembrolizumab appeared safe and provided “notable survival benefits” for select patients with recurrent glioblastoma, according to a study published in Nature Medicine.

May is Brain Cancer Awareness Month.

The addition of disulfiram and copper to chemotherapy did not result in a significant survival benefit for patients with recurrent glioblastoma, according to data published in JAMA Network Open.

The use of low-intensity pulsed ultrasound with concomitant administration of IV microbubbles can improve the delivery of albumin-bound paclitaxel and carboplatin through the blood-brain barrier, study results showed.

The FDA approved dabrafenib with trametinib for children with previously untreated low-grade glioma who harbor BRAF V600E mutations and require systemic therapy.

Tovorafenib monotherapy induced response among approximately two-thirds of patients with recurrent or progressive pediatric low-grade glioma, according to topline data released by the agent’s manufacturer.

The addition of an autologous tumor lysate-loaded dendritic vaccine to standard care extended OS among certain patients with glioblastoma, according to results of a prospective phase 3 trial published in JAMA Oncology.

CHICAGO — Divyanshu Dubey, MBBS, discusses the use of antibody evaluations in the workup for neuropathies during a presentation at the 2022 American Neurological Association’s annual meeting.

Researchers at Massachusetts General Hospital have developed a new blood test to detect epidermal growth factor receptor mutations in patients with glioma — one of the most common brain cancers in adults.

In this edition, temperature-controlled mattresses and pillows improve sleep; how overturning Roe v. Wade affects the field of neurology; college students’ cognition altered by changing sleep patterns and more.